T-Cell Lymphoma Refractory
2 clinical trials · Condition
◉ Watch T-Cell Lymphoma Refractory
| Record | Firm | Date |
|---|---|---|
| Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma (NCT03552692) | Fondazione Italiana Linfomi - ETS | 2018-09-25 |
| Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma (NCT03046953) | University of Birmingham | 2017-12-08 |
Track T-Cell Lymphoma Refractory automatically
Every clearance here is in the API, with alerts when new ones post.